Global Approach in Safety Testing

Joseph J Degeorge

ISBN 10: 1489994076 / ISBN 13: 9781489994073

Published by Springer New York, Springer US Mär 2015, 2015

About this Item

This item is printed on demand - Print on Demand Titel. Neuware -Thisvolume will consider one of ICH¿s major categories, Safety i.e. topics relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.). Since the start of the ICH process, many guidelines have been written, but even after ICH6 no explanations have been given during a formal Congress about the background of the ICH Guidance documents. Even more important than what has been written, might have been those thoughts of the experts that are not included in the Guidance documents. Why has the guideline been written as it is written, and why have some aspects been deleted. These and other related questions are the contents of this book, written by experts who were involved in the ICH process. Furthermore, the chapters will contain discussions on the ¿lessons learnt¿ and ¿future developments¿.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 328 pp. Englisch.

Seller Inventory # 9781489994073

Bibliographic Details

• Title: Global Approach in Safety Testing
• Publisher: Springer New York, Springer US Mär 2015
• Publication Date: 2015
• Language: English
• ISBN 10: 1489994076
• ISBN 13: 9781489994073
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 235W x 155H x 18D millimeters 235 millimeters width by 155 millimeters height by 18 millimeters depth
• Weight: 499 grams

About this title

Synopsis

This volume will consider one of ICH’s major categories, Safety i.e. topics relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.). Since the start of the ICH process, many guidelines have been written, but even after ICH6 no explanations have been given during a formal Congress about the background of the ICH Guidance documents. Even more important than what has been written, might have been those thoughts of the experts that are not included in the Guidance documents. Why has the guideline been written as it is written, and why have some aspects been deleted. These and other related questions are the contents of this book, written by experts who were involved in the ICH process. Furthermore, the chapters will contain discussions on the “lessons learnt” and “future developments”.

About the Author

Dr. Jan Willem van der Laan was from 1990-2007 heading the Section Pharmacology and Toxicology Assessment at the National Institute for Public Health and the Environment (RIVM, Bilthoven). In this function he was responsible for the advice on non-clinical safety aspects for the Netherlands ‘College’, the Medicines Evaluation Board. Since September 2007 he is still senior assessor in pharmacology and toxicology. He was from 2002-2010 project leader of the Teratology Information Service at the Institute. He moved in 2012 to the Medicines Evaluation Board located in Utrecht, but his role as senior assessor has not been changed. On behalf of this Board he is a member and vice-chair of the Safety Working Party (SWP) of the CHMP. His contributions to the International Conference on Harmonization started in early 1992 when he became a member of the Expert Working Group on Carcinogenicity Testing. Later on he became EU rapporteur for another topic in the Safety area, i.e. Immunotoxicology. In 2011 he finished as the EU rapporteur the Addendum for the Preclinical testing of Biotechnology-derived Proteins (ICH S6). In 2012 he is again involved in the new start of a topic on Carcinogenicity.

Joseph J. DeGeorge has a Ph.D. in Pharmacology from SUNY, Upstate Medical Center, Syracuse, NY, was a  Postdoctoral Fellow at UNC, Chapel Hill, NC, and Burroughs-Wellcome Research Institute,  and was a Senior Staff Fellow at the NIH/NIA in the Laboratory of Neuroscience. He has been actively engaged in the Safety and Multidisciplinary topics of the ICH as an Expert, Topic Rapporteur, and Safety Lead on numerous topics since the early 1990s. He is  still actively engaged in ICH as of 2012.  He has served these roles originally as a Food and Drug Administration representative and, following a brief hiatus, returned to the ICH as a PhRMA representative. He began his participation in the ICH process while serving as a Pharmacology and Toxicology reviewer inthe Neuropharmacology Division, CDER, FDA and took on increasing responsibility as his career progressed, culminating in the role of FDA ICH Safety Lead and Associate Director for Pharmacology and Toxicology for the Office of New Drugs, CDER/FDA.  He joined the pharmaceutical industry in 2002, and has been Vice President of Global Safety Assessment at Merck &Co. since 2004.  He also serves as the PhRMA Lead for ICH Safety topics, participating in the development of numerous new and revised ICH Safety Guidance's with a goal of enabling the safe and efficient development of new medicinal products.